Tags

,

Rather than bargain with a single maker, the pharmacy benefits manager says it will offer both Repatha and Praluent, promising but expensive products.


from NYT > Business Day http://ift.tt/1Q5NxTS
via IFTTThttp://ift.tt/1jbQRm6 http://ift.tt/IP98QF

Advertisements